CARDIOVASCULAR

accessibility

Overview

Supera™ Peripheral Stent

The Supera™ Peripheral Stent is indicated for the superficial femoral artery (SFA) and the proximal popliteal artery. Engineered by a unique interwoven wire technology, this nitinol stent offers physicians unmatched clinical outcomes^5-16 across varied lesion complexities and lengths.^1-4

To learn more about Supera™ Stent, simply request a free demonstration and your local Abbott representative will be in touch shortly.

Results Matter

The Supera™ Stent is known for the excellence of its clinical outcomes during percutaneous transluminal angioplasty (PTA) procedures, since this peripheral stent has been studied in more than 2,000 patients and 17 studies worldwide.^3,5-16

PATENCY (K-M) AT 1 YEAR

When nominally deployed*

FREEDOM FROM TLR AT 3 YEARS

When nominally deployed*

*Nominal deployment is defined as the stent length upon deployment being within +/- 10% of the labeled stent length. This data is from a non-powered post-hoc analysis.

Demonstrates excellent clinical outcomes

Supera™ Stent demonstrated excellent 1 yr patency and 3 yr freedom from TLR in the SUPERB trial.⁵

1

Unmatched clinical outcomes

Demonstrated unmatched clinical outcomes in simple lesions across US pivotal stent trials^5-20

2

Consistent across lesion length

Exhibits consistent 1-year primary patency results regardless of lesion length^17-25

3

Strong outcomes in calcification

Reveals strong clinical outcomes in severely calcified lesions at year 3 years⁵

^{* Study reported a majority with Trans-Atlantic Inter-Society Consensus Document (TASC) A & B lesions and/or Rutherford class 2 or 3 lesions}

Design Matters

Unlike any other stent design platform, the Supera™ Stent is uniquely designed to keep vessels open with its distinct platform, created by interwoven individual, flexible nitinol wires

High Compression Resistance²⁶

4x greater strength for compression resistance—so it can maintain a round, open lumen, which can be especially beneficial in calcified lesions

Low Chronic Outward Force²⁶

With 1:1 stent to vessel sizing, low chronic outward force results in minimal vessel injury²⁸

High Flexibility²⁷ and Fracture Resistance⁵

Unparalleled flexibility,²⁷ which mimics the natural structure and movement of the anatomy^29-31

Zero stent fractures reported at 1 year in over 2,000 patients across 17 studies^3,5-20

$High flexibility and fracture resistance$

REFERENCES
1. Treitl, K.M., et al. European Radiology.2017; 10.1007.
2. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267
3. Brescia AA. et al., J Vasc Surg. 2015 Jun;61(6):1472-8
4. Palena L.M. et al. Catheterization and Cardiovascular Intervention.2016.
5. Garcia L. et al., Catheterization and Cardiovascular Interventions 2017 Jun 1;89(7):1259-1267.
6. Gray W. et al., Lancet 2018;392:1541-51.
7. Dake M. et al., Circulation. 2016;133:1472-1483.
8. Laird J. et al., Circ Cardiovasc Interv. 2010;3:267-276.
9. Laird J et al., J Endovasc Ther. 2012;19:1–9.
10. S.M.A.R.T. Control IFU.
11. Jaff, M., SMART Nitinol Self-Expanding Stent in the Treatment of Obstructive Superficial Femoral Artery Disease: Three-year Clinical Outcomes from the STROLL Trial. ISET 2014.
12. Matsumura J et al., J Vasc Surg 2013;58:73-83.
13. Rocha-Singh, K., 3-Year Results of the DURABILITY II Study. VIVA 2013.
14. US Innova IFU.
15. US Pulsar IFU.
16. Ohki T. et al. J Vasc Surg. 2016 Feb;63(2):370-6.
17. Treitl, K.M., et al. European Radiology. 2017; 10.1007
18. Garcia L. et al. Circ Cardiovasc Interv. 2015;8:e000937
19. Scheinert D. et al., J Endovasc Ther. 2011 Dec;18(6):745-52.
20. San Norberto EM. et al., Ann Vasc Surg. 2017 May;41:186-195.
21. Werner M. et al., EuroIntervention. 2014 Nov;10(7):861-8.
22. George JC. et al., J Vasc Interv Radiol. 2014 Jun;25(6):954-61.
23. Montero-Baker M. et al., J Vasc Surg. 2016 Oct;64(4):1002-8.
24. Brescia A. et al. J Vasc Surg. 2015 Mar 6. pii: S0741-5214(15)00132-9
25. Palena L.M. et al. Catheterization and Cardiovascular Interventions 2016
26. Competitors tested include Astron Pulsar-18, Complete SE, EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Test(s) performed by and data on file at Abbott.
27. Flexibility is defined as kink resistance. Competitors tested include Astron Pulsar-18, Complete SE, EverFlex, Innova, LifeStent, Misago, S.M.A.R.T., and Zilver PTX. Test(s) performed by and data on file at Abbott
28. Zhao HQ et al. Cardiovasc Intervent Radiol. 2009;32(4):720-6
29. Arena F. et al., J Vasc Med Surg. 2013:1;116.
30. Chen Y. et al., J Vasc Surg 2014;59:384-91.
31. Test(s) performed by and data on file at Abbott

Important Safety Information

MAT-2008210 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False

accessibility

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YES NO

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YES NO

accessibility

YES NO

accessibility

Precautions

Please be sure to read it.

The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.

The information provided here is not intended to provide information to patients and the general public.

Are you a healthcare professional?

Test

yes no

SUPERA™ STENT

Results Matter. Design Matters.

Supera™ Peripheral Stent